Description
Sheel Biotech Limited to be transferred from trade for trade segment (series: ST) to rolling segment (Series: SM) effective October 24, 2025.
Summary
Sheel Biotech Limited will be transferred from the trade for trade segment (series: ST) to the rolling segment (Series: SM) effective October 24, 2025. This follows Exchange Circular no. NSE/CML/70685 dated October 07, 2025 and is pursuant to SEBI guidelines under circular reference no. CIR/MRD/DP/02/2012 dated January 20, 2012.
Key Points
- Security Symbol: SHEEL
- Company Name: Sheel Biotech Limited
- Movement from Trade for Trade segment (Series: ST) to Rolling segment (Series: SM)
- This is a routine post-IPO segment transfer for an SME listing
Regulatory Changes
No new regulatory changes. This action is pursuant to existing SEBI guidelines (CIR/MRD/DP/02/2012 dated January 20, 2012) governing segment transfers for securities.
Compliance Requirements
No specific compliance requirements for market participants. This is an administrative segment transfer managed by the Exchange.
Important Dates
- Circular Date: October 08, 2025
- Effective Date: October 24, 2025 - Sheel Biotech Limited transfers to rolling segment
Impact Assessment
Minimal market impact. This is a standard procedural transfer for a single SME stock following its IPO. The move to rolling segment allows for normal T+2 settlement instead of trade-for-trade settlement, potentially improving liquidity for the security. Impact is limited to traders and investors specifically dealing with SHEEL stock.
Impact Justification
Routine segment transfer for a single SME stock from trade-for-trade to rolling segment, limited market-wide impact